This multi-author book has been published in consonance with the growing interest in translational medicine (TM). It consists of 11 chapters. The first chapter introduces and explains the concept of TM. It takes us through the history of TM and analyses the obstacles, low output syndrome in terms of true medical innovations as well as its implications on big pharmaceutical companies. In short, ...

Nick Lemoine is at the Institute of Cancer, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK. It is evident that clinician-scientists are high-fliers, but also increasingly obvious that they are rare and endangered Translation requires individuals who are fluent in two languages, and this is equally true of translational medicine, for which clinicia...

H istoric advances in biomedical research provide both unprecedented insights into the pathogenesis of human diseases and the challenge to translate these insights effi ciently into improved health. Meeting this challenge requires the creation of a robust translational and clinical research enterprise [1], which, in turn, depends critically on the ability of academic medicine to produce and sup...

Advancements in high-throughput technology and computational power have brought about significant progress in our understanding of cellular processes, including an increased appreciation of the intricacies of disease. The computational biology community has made strides in characterizing human disease and implementing algorithms that will be used in translational medicine. Despite this progress...

Knowledge and resources derived from veterinary medicine represent an underused resource that could serve as a bridge between data obtained from diseases models in laboratory animals and human clinical trials. Naturally occurring disease in companion animals that display the defining attributes of similar, if not identical, diseases in humans hold promise for providing predictive proof of conce...

While many "benchtop-to-bedside" research pathways have been developed in "Type I" translational medicine, vehicles to facilitate "Type II" and "Type III" translation that convert scientific data into clinical and community interventions designed to improve the health of human populations remain elusive. Further, while a high percentage of physicians endorse the principle of citizen leadership,...

The IMPAKT 2015 Breast Cancer Conference was designed for researchers and clinicians by the Breast International Group (BIG) and the European Society for Medical Oncology (ESMO). The event was held on 7-9 May in Brussels, Belgium, bringing together approximately 525 participants with a special interest in translational science and state-of-the-art applications in the clinical setting. Oncologis...

In 2000 the United States launched the National Nanotechnology Initiative and, along with it, a well-defined set of goals for nanomedicine. This Perspective looks back at the progress made toward those goals, within the context of the changing landscape in biomedicine that has occurred over the past 15 years, and considers advances that are likely to occur during the next decade. In particular,...

Quantitative pharmacology (QP) applications in translational medicine, drug-development, and therapeutic use were crowd-sourced by the ASCPT Impact and Influence initiative. Highlighted QP case studies demonstrated faster access to innovative therapies for patients through 1) rational dose selection for pivotal trials; 2) reduced trial-burden for vulnerable populations; or 3) simplified posolog...